MTOR and breast carcinoma: Deregulation of the mTOR (mammalian target of rapamycin) pathway has been widely reported in TNBCs when compared to ER+/PR+/HER2 overexpressing breast cancers, and is correlated to the poor outcome among TNBC patients [23].